[Novel controllers of airway obstruction in COPD patients].

Abstract

For improving effectiveness of chronic obstructive pulmonary disease (COPD) therapy is necessary to influence on pharmacologic receptors in the complementary way and to reduce the dose frequency. The once-daily dose administration is an important step which may allow to enhance of patients compliance. Novel long-acting bronchodilators--beta2-agonists or ultra long-acting beta2-agonists (LABAs) such as indacaterol and carmoterol--are under clinical application for the treatment of COPD patients. Moreover, some new long-acting antimuscarinic agents (LAMA) (aclidinium, glycopyrrolate) and dual-action ultra LABA+LAMA combination products are under development. The main target of therapeutic research is to produce a dimmer molecule known as M3 antagonist-beta2 agonist (MABA) bronchodilators which will open the door for a new range of combination products.

• Authors: Tadeusz Płusa
• Journal: Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego (Pol Merkur Lekarski) Vol. 30 Issue 175 Pg. 5-9 (Jan 2011) ISSN: 1426-9686 [Print] Poland
• Vernacular Title: Nowe leki kontrolujace obturacje dróg oddechowych u chorych na POChP.
• PMID: 21542237 (Publication Type: Editorial, English Abstract)

Chemical References

• Amphetamines
• Bronchodilator Agents
• Drug Combinations
• Hydroxyquinolines
• Indans
• Muscarinic Antagonists
• Quinolones
• indacaterol
• carmoterol

Topics

• Airway Obstruction (drug therapy)
• Amphetamines (administration & dosage)
• Bronchodilator Agents (administration & dosage)
• Drug Administration Schedule
• Drug Combinations
• Humans
• Hydroxyquinolines (administration & dosage)
• Indans (administration & dosage)
• Muscarinic Antagonists (administration & dosage)
• Patient Compliance
• Pulmonary Disease, Chronic Obstructive (drug therapy, physiopathology)
• Quinolones (administration & dosage)